A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Inclusion Criteria

• •Clear cell renal cancer histologically proved (association with other histologic component are permitted)
• •Patients of good or intermediate prognostic, according to Heng criteria
• •Extracerebral metastatic disease documented with imagery
• •Patients treated in first or second line systemic therapy
• •Oligoprogressive disease documented with imagery, defined as the emergence or progression of 1 to 3 metastases and progression localized in up to 2 organs
• •Oligoprogressive disease confirmed with 2 CT scans performed 2 months apart
• •At least one measurable progressing metastasis according to R.E.C.I.S.T. criteria v1.1
• •All oligoprogressive target lesions measuring ≤ 4 cm
• •Good general condition (WHO performance status ≤ 2)
• •All progressive lesions have to be accessible to SRT, performed concurrently or sequentially
• •No contraindication to systemic therapy and stereotactic radiation therapy
• •Patients aged 18 years or older
• •Signed informed consent form
• •Patients affiliated to the social security system